Source: Targeted Oncology, May 2025
The investigational new drug application for LP-184 has been cleared by the FDA. With this clearance, a phase 1b/2 trial of the agent will begin in triple-negative breast cancer (TNBC). The trial will assess LP-184 as monotherapy and in combination with a PARP inhibitor. With an average survival of 10 to 18 months for patients with newly diagnosed metastatic TNBC, LP-184 could address a significant unmet medical need.
“This IND clearance for LP-184 in a phase 1b/2 study represents a pivotal advancement in our mission to bring precisely targeted, AI-developed medicines to patients with aggressive cancers and limited treatment options," said Panna Sharma, chief executive officer and president of Lantern Pharma, in a press release. “The strategic design of our clinical program reflects both the compelling mechanistic rationale and the encouraging data supporting LP-184’s potential in TNBC."